JP Morgan Reinstates Underweight on Emergent BioSolutions
Emergent BioSolutions (EBS) Q2 2026 Earnings Call Transcript
HC Wainwright & Co. Maintains Buy on Emergent BioSolutions, Lowers Price Target to $10
Emergent Biosolutions Q2 Earnings Call Highlights
Emergent BioSolutions Inc. (EBS) Q2 2026 Earnings Call Transcript
Emergent BioSolutions Inc. Q2 2026 Earnings Call Summary
Emergent BioSolutions (NYSE:EBS) Beats Q2 Estimates, but Stock Drops on NARCAN Impairment and Restructuring Costs
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment
Emergent BioSolutions Inc. 2026 Q2 - Results - Earnings Call Presentation
Emergent BioSolutions Sees Q3 Sales $110.000M-$130.000M vs $209.000M Est
Emergent BioSolutions Lowers FY2026 Sales Guidance from $720.000M-$760.000M to $645.000M-$675.000M vs $733.050M Est
Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
Emergent BioSolutions Secures $52.7M U.S. Government Contract Modification For ACAM2000 Smallpox And Mpox Vaccine Supply
Emergent BioSolutions Inc. (EBS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
Emergent BioSolutions Wins $64.5M U.S. HHS Contract Modification To Supply Botulism Antitoxin BAT Under Existing 10-Year Agreement
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.